Background: The purpose of this study was to investigate the performance of the Memorial Sloan Kettering Cancer Center salivary carcinoma nomograms predicting overall survival, cancer-specific survival, and recurrence with an external validation dataset.
Therefore, the use of nomograms may be useful in the treatment of malignancies of major salivary glands. Nomograms are statistical tools that predict clinical outcomes for an individual based on a number of variables, commonly patient and histopathological factors. 4 They are typically created using regression analysis and are a graphical description of a complex predictive model. 5 They have been reported to outperform experienced clinicians in some settings 6 and have been used in clinical trial inclusion criteria and in the National Comprehensive Cancer Network guidelines. 7 They may also be included in the new AJCC staging systems for some cancer types. 8 The steps involved in building a nomogram include defining the population, specifying the outcome of interest, and then identifying potential factors that influence the outcome. After building the nomogram using regression analysis, the model is then validated. This can be done with internal validation using bootstrapping or by using an external dataset. 9 Major salivary gland nomograms for overall survival, 10 cancer-specific survival, 10 and recurrence 11 have recently been published by our institution. A comprehensive list of potential factors, created in consultation with an expert panel and consultation with the literature, were considered as potential covariates and used to collect initial data for the nomogram generation cohort. These were then examined with univariate analysis to identify potential covariates. The most predictive factors were combined into multiple variable combinations and then assessed. Factors with the highest predictive value based on a step-down model reduction method were parsimoniously selected, limited by the number of events. The nomogram for overall survival used age, maximum tumor dimension and clinical T4 classification, grade, and PNI as covariates. The nomogram for cancer-specific survival used grade, PNI, clinical T4 classification, positive nodes, and margin status. The nomogram for recurrence used age, grade, vascular invasion, and presence of positive lymph nodes.
To test the performance of these nomograms, internal validation was done using bootstrapping. In bootstrapping, random samples are drawn from the original dataset to create a test dataset, and this is repeated making a larger number of test datasets or indices. An average is taken of the model's performance in all the indices and compared to the original. The performance of the model is always best on the original dataset and the difference between the two is an estimate of the over fit and provides an assessment of how the model might perform in the future. However, the gold standard validation of a nomogram model is the evaluation of its performance on an external dataset, a dataset that was not used in constructing the model. This provides the best evidence for the external applicability of the model and is critical in the application of these models to other patient populations. The purpose of our study was to describe the validation of these nomograms using an external dataset of patients from a contemporary cohort of patients. This will provide evidence for the generalizability of nomograms and provide support for the clinical application of these nomograms.
| MA TERI A LS AND M ETH ODS
Approval was granted from the Memorial Sloan Kettering Cancer Center Institutional Review Board to perform this study. Patients included in the initial nomogram studies (nomogram development) had primary treatment at our institution with surgery and adjuvant treatment if indicated. Indications for postoperative radiotherapy were patients with pathological T3/4 classification tumors, positive neck disease, PNI and LVI, positive margins, and high-grade tumors. 10 Patients who had prior open biopsy (incisional or excisional), had recurrent tumors, prior surgery, or prior radiotherapy were excluded from this study. This cohort included patients treated between 1985 and through 2009. In our previous studies, the nomograms of recurrence, overall survival, and cancer-specific survival were generated by assessing predictive factors using univariate analysis. The most predictive factors were combined into multiple variable combinations and then assessed. Factors with the highest predictive value based on a stepdown model reduction method were parsimoniously selected, limited by the number of events. Clinical knowledge and known clinically important factors were used to decide which covariates were included in the final model. The nomogram for overall survival was validated by using the internal validation technique of bootstrapping. The concordance index (C-index) score was 0.809 (95% CI 0.772-0.849). The same techniques were used for cancer-specific survival and recurrence nomograms. The C-index for these nomograms were 0.856 (95% CI 0.852-0.866) and 0.850 (95% CI 0.813-0.888), respectively. The graphical representation can be seen in Figure 1A -C.
In the current study, the same inclusion and exclusion criteria were used to generate the external validation dataset. This included patients treated between 2010 and the end of 2015. A validation dataset should be similar in terms of cancer types and patient demographics but different in terms of another important factor, such as historical time or geographic location. 9 A more recent cohort of patients whose data had not been used in the original nomogram generation was used. In both cohorts, a retrospective analysis of the patient record was used to extract demographic, clinical, tumor, treatment, and outcome data. Data were stored in Caisis (Biodigital), which is oncologic open source data software on a secure institutional network. 2 The LVI was defined as the presence of malignant cells in lymphatic or vascular vessels on histological examination. The PNI was defined as tumor cells invading and spreading around the space surrounding nerves. 12 
| Details of variables in nomogram

| Definitions of outcomes
Overall survival was calculated from the day of operation to the last known follow-up date or date of death found in the F IGUR E 1 A, Nomogram for prediction of 10-year overall survival probability for major salivary gland malignancy. The corresponding points for each variable are determined and then the sum of these is plotted on the total points bar. The 10-year overall survival probability is then determined by tracing down from the total points score. B, Nomogram for prediction of 5-year cancer-specific mortality for major salivary gland malignancy. The corresponding points for each variable are determined and then the sum of these is plotted on the total points bar. The 5-year cancer-specific mortality probability is then determined by tracing down from the total points score. C, Nomogram for prediction of 7-year recurrence probability for major salivary gland malignancy. The corresponding points for each variable are determined and then the sum of these is plotted on the total points bar. The 7-year recurrence probability is then determined by tracing down from the total points score hospital records or social security index. Cancer-specific survival was calculated from the day of surgery until last known follow-up or death from salivary cancer reported in the patient record. Recurrence was calculated from the day of surgery until the first local, regional, or distant recurrence reported in the patient record.
| Statistical analysis
Nomograms for overall survival, cancer-specific survival, and recurrence have previously been reported 10, 11 for the salivary gland carcinoma nomogram-generation cohort (original cohort) and are presented in Figure 1A -C.
Comparison of the original cohort with the validation cohort was performed, comparing patient demographics and clinopathological factors. The chi-square test of association or the Fisher's exact test was used for the comparison of categorical variables and the Wilcoxon rank test for continuous variables.
Nomogram validation was assessed by plotting a calibration curve and measuring the discrimination of nomograms with the C-index. The calibration curve is generated by plotting the predicted probability against actual probability of the outcome. Discrimination of a model is the ability of the model to separate patients with different outcomes. The value of the C-index varies between 0.5 and 1.0, with 0.5 indicating random chance and 1.0 indicating perfect ability to discriminate.
| R ES ULT S
| Clinical characteristics
The external validation cohort consisted of 123 patients with a median age of 60 years. Male patients accounted for 52% of the nomogram generation cohort and 48% of the validation dataset. There were no significant differences in age, sex, clinical T classification, or clinical N classification between the cohorts The T2 tumors were the most common tumor T classification in both cohorts, accounting for 43% in the generation cohort and 42% in the validation cohort. The proportion of patients with clinical T4 tumors was 11% in the original cohort and 10% in the validation cohort. The majority of patients had clinically negative neck lymph node status, 88% in the nomogram generation cohort and 80% in the validation cohort (Table 1) .
| Tumor characteristics
Mucoepidermoid carcinoma was the most common histology type in both cohorts, accounting for 31% of patients in the original cohort and 25% in the validation cohort. There was a larger proportion of carcinoma ex pleomorphic adenoma in the original cohort (19.6%) compared to the validation cohort (5.7%). However, the validation cohort had a larger proportion of adenoid cystic carcinoma, myoepithelial carcinoma, and salivary duct carcinoma (Figure 2 ).
The original cohort had less low/intermediate-grade cancers (34.6% vs 64.2%; P 5 .006). There was less LVI in the validation cohort (14.7% vs 22.2%; P < .001) and the mean max size was smaller (2.2 cm vs 2.5 cm; P 5 .004). There were no significant differences in the proportions of patients with PNI, surgical positive margins, and presence of pathological cervical lymph node metastases ( Table 2 ).
| Outcomes
The median follow-up of survivors in the original cohort was 45.6 months, and 19 months in the validation cohort (P < .001). There were 117 deaths, 70 recurrences, and 58 cancer-specific F IGUR E 1 Continued deaths in the original cohort. In the validation cohort, there were 24 deaths, 19 recurrences, and 18 cancer-specific deaths.
| Nomogram validation
The C-indices with 95% CI for the original cohort were 0.809 (0.772-0.849) for overall survival, 0.856 (0.852-0.866) for cancer-specific survival, and 0.850 (0.813-0.888) for recurrence.
Validation of the nomograms using the external dataset showed the C-index for overall survival with 95% CIs to be 0.833 (0.758-0.908). Cancer-specific survival had a C-index of 0.897 (0.717-0.898) and the recurrence C-index was 0.844 (0.768-0.920).
The calibration curves for predicted 3-year recurrencefree probability, cancer-specific survival, and overall survival can be seen in Figure 3A -C. The calibration plots were generated by grouping patients into several groups, in which the average predicted 3-year overall survival/cancer-specific survival/recurrence-free probabilities were able to be compared with the actual event survival rate. The number of groups selected is arbitrary depending on the cohort size but, by convention, 4 groups are usually chosen to do the comparison. In this study, the number of events are small, to ensure there was at least one event within each group, 3 groups were used for overall survival and recurrence; whereas 2 groups were used for cancer-specific survival as the number of cancer-specific death was the smallest. The dots in the calibration plots showed the average predicted probabilities, and the vertical bars were the corresponding 95% CIs. 
| D IS C US S I ON
Salivary gland carcinomas are a particularly heterogeneous group of tumors. This makes estimating survival and recurrence challenging. Staging systems have been used in the past but these can be imprecise for an individual. Therefore, the Memorial Sloan Kettering Cancer Center nomograms for overall survival, cancer-specific survival, and recurrence were created. The purpose of this study was to validate these nomograms on an external dataset. The C-index for the validation cohort for overall survival, cancer-specific survival, and recurrence nomograms were all over 0.8 suggesting they all performed well. Differences in the C-index are influenced by differences in cohort populations, the variation in the covariates, and the follow-up length. A larger difference in underlying population characteristics and covariates can cause a decrease in the concordance score. There were some differences between the cohorts on univariate analysis, which included the proportion of high-grade tumors and the presence of LVI. There were also some differences in the proportion of histological diagnoses between cohorts. Such differences could have resulted in a lower estimation of the C-indexes. Shorter follow-up tends to increase a concordance score. In our validation cohort, there was a significantly shorter follow-up time and, therefore, this may have improved the concordance scores. Despite these differences, the nomograms performed well indicating their potential for generalizability with other populations.
The Memorial Sloan Kettering Cancer Center salivary malignancy nomograms are the first to be published and externally validated in the literature giving the potential to provide personalized, tailored information to patients. The alternative approach to prognostication involves using staging systems in which patients are grouped based on just clinical variables or on a clinically generated score. Examples of these for predicting recurrence are the AJCC staging system, 3 Carrillo score, 13 and Vander Poorten score. 14 These 3 prognostic scoring systems have been tested on an external dataset of parotid cancers from an Asian institution. 15 They were Our study does have a number of limitations. Both the original cohort nomograms and the validation analysis are all based on retrospective data collection from the same institution. Therefore, the data are susceptible to the risk of selection bias and by the bias introduced from single institution data. Further validation on a geographically different cohort could strengthen the evidence for the nomograms. The validation cohort is based on a recent group of patients and, therefore, has a shorter follow-up period. Therefore, the validation probabilities for calibration were based on 3-year probabilities. This may be a potential source of bias because with a shorter follow-up time there will be fewer events, such as death and recurrences. This can affect the accuracy and size of the CIs, as in this study, leading to wider CIs. The calibration plots compare the predicted survival probability with the actual event survival rate within each group. The calibration plot is sensitive to the number of groups selected. In our study, due to the small number of events especially for cancer-specific survival, the patients were not evenly distributed into 4 groups as usual because using 4 groups would result in no events in some groups making it difficult to draw the calibration curve.
Hence, the number of groups and number of patients in each group have been adjusted in order to successfully generate the calibration curve. The difference in the width of the confidence bars reflected the difference in the number of patients in each of the groups. As a result, the overall survival nomogram overpredicted the 3-year overall survival probabilities especially for the 2 groups of patients with the low survival probabilities.
Nomogram use in clinical practice is a useful tool and adjunct in discussions with patients. However, they are currently not used routinely in making treatment decisions or choosing adjuvant therapy. This study shows that our salivary nomogram can be successfully validated on an external dataset suggesting a wider applicability. However, further validation on external datasets from different countries is required.
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